MX2020006490A - Compuestos macrociclicos para tratar enfermedades. - Google Patents

Compuestos macrociclicos para tratar enfermedades.

Info

Publication number
MX2020006490A
MX2020006490A MX2020006490A MX2020006490A MX2020006490A MX 2020006490 A MX2020006490 A MX 2020006490A MX 2020006490 A MX2020006490 A MX 2020006490A MX 2020006490 A MX2020006490 A MX 2020006490A MX 2020006490 A MX2020006490 A MX 2020006490A
Authority
MX
Mexico
Prior art keywords
treating disease
macrocyclic compounds
cancer
methods
present disclosure
Prior art date
Application number
MX2020006490A
Other languages
English (en)
Inventor
Han Zhang
Wei Deng
Jane Ung
Jingrong Jean Cui
Evan W Rogers
Dayong Zhai
Jeffrey Whitten
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of MX2020006490A publication Critical patent/MX2020006490A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a ciertos derivados macrocíclicos, las composiciones farmacéuticas que los contienen y los métodos para usarlos para tratar enfermedades, como el cáncer.
MX2020006490A 2017-12-19 2018-12-18 Compuestos macrociclicos para tratar enfermedades. MX2020006490A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762607528P 2017-12-19 2017-12-19
US201862727124P 2018-09-05 2018-09-05
US201862779283P 2018-12-13 2018-12-13
PCT/US2018/066158 WO2019126121A1 (en) 2017-12-19 2018-12-18 Macrocyclic compounds for treating disease

Publications (1)

Publication Number Publication Date
MX2020006490A true MX2020006490A (es) 2020-08-17

Family

ID=66992951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006490A MX2020006490A (es) 2017-12-19 2018-12-18 Compuestos macrociclicos para tratar enfermedades.

Country Status (26)

Country Link
US (3) US10745416B2 (es)
EP (2) EP3728271B1 (es)
JP (2) JP7194188B2 (es)
KR (1) KR20200101358A (es)
CN (1) CN111511746B (es)
AU (1) AU2018392332B2 (es)
BR (1) BR112020012319A2 (es)
CA (1) CA3083674A1 (es)
CL (1) CL2020001632A1 (es)
DK (1) DK3728271T3 (es)
EC (1) ECSP20033467A (es)
ES (1) ES2929467T3 (es)
HR (1) HRP20221502T1 (es)
HU (1) HUE060711T2 (es)
IL (1) IL275265B2 (es)
JO (1) JOP20200152A1 (es)
LT (1) LT3728271T (es)
MX (1) MX2020006490A (es)
PH (1) PH12020550901A1 (es)
PL (1) PL3728271T3 (es)
PT (1) PT3728271T (es)
RS (1) RS63787B1 (es)
SG (1) SG11202005590PA (es)
SI (1) SI3728271T1 (es)
TW (1) TW201930312A (es)
WO (1) WO2019126121A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE064659T2 (hu) 2015-11-02 2024-04-28 Blueprint Medicines Corp RET inhibitorai
HUE056615T2 (hu) 2017-10-18 2022-02-28 Incyte Corp Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
PT3710438T (pt) 2017-12-19 2021-11-22 Bristol Myers Squibb Co Ácidos carbamoil ciclohexílicos n-ligados a triazol como antagonistas de lpa
BR112020020273A2 (pt) 2018-04-03 2021-04-06 Blueprint Medicines Corporation Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
JP7490635B2 (ja) 2018-08-10 2024-05-27 ブループリント メディシンズ コーポレイション Ｅｇｆｒ変異がんの処置
MX2021004538A (es) 2018-10-22 2021-09-10 Esker Therapeutics Inc Inhibidores de tyk2 y sus usos.
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
PE20220135A1 (es) * 2019-06-19 2022-01-27 Turning Point Therapeutics Inc Polimorfos de un inhibidor de cinasas macrociclicas
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
KR20220133869A (ko) * 2019-12-03 2022-10-05 터닝 포인트 테라퓨틱스, 인크. 질환 치료에 사용하기 위한 거대고리
WO2021244609A1 (zh) 2020-06-04 2021-12-09 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
WO2023060022A1 (en) * 2021-10-05 2023-04-13 Turning Point Therapeutics, Inc. Synthesis of macrocyclic compounds
WO2024017380A1 (zh) * 2022-07-22 2024-01-25 南京明德新药研发有限公司 含三并环的大环类化合物及其应用
WO2024040131A1 (en) * 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0690843T3 (da) * 1993-03-25 2000-11-13 Upjohn Co Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet
IL111850A (en) 1993-12-07 2002-11-10 Lilly Co Eli 3, 4 - Bite (indolyl) from cyclic amides that inhibit kinase C protein, their preparation and boils that contain
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ES2245994T3 (es) 2000-12-08 2006-02-01 Ortho-Mcneil Pharmaceutical, Inc. Compuestos macro-heterociclicos utilizados como inhibidores de quinasa.
AU2009288021B2 (en) 2008-09-08 2015-06-18 Merck Patent Gmbh Macrocyclics pyrimidines as Aurora kinase inhibitors
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
ES2588504T3 (es) 2008-10-22 2016-11-03 Array Biopharma, Inc. Compuestos de pirazolo[1,5-a]pirimidina sustituidos como compuestos intermedios en la síntesis de inhibidores de TRK quinasa
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
EP2488521B1 (en) 2009-10-13 2013-12-18 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
SG10201506591TA (en) * 2010-05-20 2015-09-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
KR20140059236A (ko) 2011-08-19 2014-05-15 머크 샤프 앤드 돔 코포레이션 Hcv 프로테아제 억제제의 결정 형태
HUE027318T2 (en) 2011-09-30 2016-10-28 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
MX350844B (es) 2012-03-06 2017-09-22 Pfizer Derivados macrocíclicos para el tratamiento de enfermedades proliferativas.
JP6418949B2 (ja) 2012-03-09 2018-11-07 レクシコン ファーマシューティカルズ インコーポレイテッド イミダゾ［１，２−ｂ］ピリダジン系化合物、それを含む組成物、及びそれらを使用する方法
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
UA121206C2 (uk) 2014-01-24 2020-04-27 Турнінґ Поінт Терапьютикс, Інк. Діарильні макроцикли як модулятори протеїнкіназ
DK3172213T3 (da) * 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc Makrocykliske kinasehæmmere og anvendelser deraf
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
JP6917974B2 (ja) 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
EP3733187A1 (en) 2015-07-21 2020-11-04 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
CN112920201A (zh) * 2016-03-03 2021-06-08 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN106008531B (zh) * 2016-05-30 2019-01-11 上海交通大学 多环稠合大环内酰胺类化合物的抗胰腺癌用途
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
UA126158C2 (uk) 2017-07-28 2022-08-25 Тьорнінґ Поінт Терапьютикс, Інк. Макроциклічні сполуки і їх використання
HUE056615T2 (hu) 2017-10-18 2022-02-28 Incyte Corp Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok
PT3710438T (pt) 2017-12-19 2021-11-22 Bristol Myers Squibb Co Ácidos carbamoil ciclohexílicos n-ligados a triazol como antagonistas de lpa
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
GB201721235D0 (en) 2017-12-19 2018-01-31 Syngenta Participations Ag Polymorphs
WO2019126122A1 (en) * 2017-12-19 2019-06-27 Tp Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
WO2019120267A1 (zh) 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
CA3099493C (en) 2018-04-18 2023-08-22 Hitgen Inc. Macrocyclic kinase inhibitor

Also Published As

Publication number Publication date
JP7194188B2 (ja) 2022-12-21
EP4151641A1 (en) 2023-03-22
WO2019126121A1 (en) 2019-06-27
IL275265B2 (en) 2023-07-01
EP3728271A4 (en) 2021-06-23
EP3728271B1 (en) 2022-09-28
SG11202005590PA (en) 2020-07-29
BR112020012319A2 (pt) 2020-11-24
CL2020001632A1 (es) 2020-11-20
HUE060711T2 (hu) 2023-04-28
ES2929467T3 (es) 2022-11-29
US11286265B2 (en) 2022-03-29
US20200190110A1 (en) 2020-06-18
US10745416B2 (en) 2020-08-18
JOP20200152A1 (ar) 2022-10-30
IL275265B1 (en) 2023-03-01
EP3728271A1 (en) 2020-10-28
RS63787B1 (sr) 2022-12-30
JP2021506850A (ja) 2021-02-22
KR20200101358A (ko) 2020-08-27
US20200392160A1 (en) 2020-12-17
LT3728271T (lt) 2022-12-12
CN111511746B (zh) 2024-01-09
JP2023027237A (ja) 2023-03-01
AU2018392332B2 (en) 2023-08-03
PL3728271T3 (pl) 2023-01-23
CA3083674A1 (en) 2019-06-27
IL275265A (en) 2020-07-30
HRP20221502T1 (hr) 2023-03-31
AU2018392332A1 (en) 2020-06-11
PT3728271T (pt) 2022-10-06
CN111511746A (zh) 2020-08-07
SI3728271T1 (sl) 2023-01-31
PH12020550901A1 (en) 2021-05-17
DK3728271T3 (da) 2022-12-19
TW201930312A (zh) 2019-08-01
ECSP20033467A (es) 2020-09-30
US20220306652A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
ZA202004100B (en) Diaryl macrocycles as modulators of protein kinases
PH12020500033A1 (en) Macrocyclic compounds and uses thereof
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
NZ731696A (en) Method for treating cancer
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2017009608A (es) Compuestos anticancerigenos.
MX2017007318A (es) Metodos de prevencion, reduccion o tratamiento de degeneracion macular.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
TW201612183A (en) Diaryl macrocycles as modulators of protein kinases
EA202091327A1 (ru) Макроциклические соединения для лечения заболеваний